Loading data for ZNTL — first visit, this takes a few seconds.

Zentalis Pharmaceuticals, Inc. (ZNTL)

NasdaqGM: ZNTL · Real-Time Price · USD

4.00

-0.11 (-2.68%)

At close: Sep 04, 2026, 3:59 PM

4.02

+0.75%

After-hours: 7:41 PM

Alert

The price, the headline numbers and the latest news, in one place.

-2.80% (1D)

Bid	3.53
Market Cap	378M
Revenue (ttm)	n/a
Net Income (ttm)	-140M
	1.86
	-1.96
	n/a
	-2.21
P/B (ttm)	1.55
P/S (ttm)	0.00
Earnings Date	Nov 10, 2026

Ask	6.28
Volume	512,599
Avg. Volume (20D)	1,206,295
Open	4.05
Previous Close	4.11
Day's Range	3.92 - 4.19
52-Week Range	1.21 - 6.95
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 3, 2020

Employees 106

Stock Exchange NasdaqGM

Ticker Symbol ZNTL

Website https://zentalis.com

Full Company Profile

Financial Performance

In 2025, Zentalis Pharmaceuticals's revenue was 0, a decrease of -100% compared to the previous year's 67.43M. Earnings were -137.06M, a decrease of -17.35%.

Financial Statements

Earnings Surprise

Zentalis Pharmaceuticals has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.59 misses estimates by -0.11, with 11.94% YoY growth.

Next Earnings Release

Zentalis Pharmaceuticals, Inc. is scheduled to release its earnings on Nov 10, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

3 weeks ago · MT Newswires

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a

1 month ago · Zacks

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.

4 months ago · Insider Monkey

Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is one of the must-buy small cap stocks to buy. On April 10, Jefferies raised its price target on Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) from $2.50 to $6...

4 months ago · Simply Wall St.

A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone

Zentalis Pharmaceuticals (ZNTL) has drawn fresh attention after selecting a 400 mg once-daily, 5-days-on, 2-days-off dose of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer, based...

6 months ago · MarketBeat

Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon

Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC), emphas...

Page 1 of 2

Zentalis Pharmaceuticals, Inc. (ZNTL)